Overview of Algi Mabo

The following information establishes the core identity, composition, and general purpose of the medicine Algi Mabo (Sodium Metamizole).

Property	Description
Active ingredient	Sodium Metamizole (also known as Dipyrone)
Form	Tablets, Oral drops, Solution for Injection
Pharmacological class	Non-opioid analgesic, Antipyretic, Spasmolytic
Common use	Relief of significant pain and high fever
Origin	Synthetic pyrazolone derivative

Identity and Pharmacological Classification

Algi Mabo is a pharmaceutical product primarily defined by its sole active ingredient, Sodium Metamizole, which is a powerful compound recognized globally as Dipyrone. This substance is a synthetic pyrazolone derivative officially classified as a non-opioid analgesic. Its composition as a single-ingredient product ensures that the entire therapeutic effect stems from this one potent synthesized agent.

This medication has been clinically recognized for decades across various global markets, confirming its utility as a primary agent for managing severe discomfort and pyrexia. This classification places Algi Mabo in a distinct position: its chemical structure and action as a pyrazolone derivative highlight its differentiation from common NSAIDs and acetaminophen.

Forms and General Purpose

The medicine is supplied in various dosage forms to suit different patient needs, including oral preparations such as tablets and oral drops, and a sterile solution for injection. This versatility in form facilitates different routes of administration for systemic action.

The general purpose of Algi Mabo is the effective management of acute, significant pain and the reduction of elevated body temperatures. Its defining feature is its triple action: it reduces pain signals (analgesia), normalizes fever (antipyresis), and helps relieve pain associated with muscle tension by relaxing smooth muscle tissue (spasmolysis). This combined profile makes it particularly useful in scenarios requiring concurrent relief of fever and pain with a spasmodic component.

What side effects are possible with Algi Mabo?

Possible Side Effects and Safety Information

The safety profile of Algi Mabo (Sodium Metamizole) is defined by categories of adverse reactions, primarily focusing on rare but severe effects on the blood and immune systems, as documented in official regulatory labeling.

Serious Adverse Reactions

The most significant safety concern listed in regulatory documents is the risk of Agranulocytosis—a severe reduction in white blood cells that can lead to life-threatening infections. This reaction is classified as Very Rare in many regulatory documents, and it is officially noted as not dose-dependent, meaning it can occur at any time during treatment. Other serious effects include Aplastic Anaemia, which is bone marrow failure, and severe hypersensitivity events, such as Anaphylactic Shock and Stevens-Johnson Syndrome (SJS).

Organ System Effects and Frequency

Adverse effects are grouped by System-Organ Class (SOC) and are assigned official frequencies:

System-Organ Class (SOC)	Examples of Officially Listed Effects	Frequency Classification
Blood and Lymphatic	Agranulocytosis, Leucopenia, Pancytopenia	Rare to Very Rare
Immune System	Anaphylactic reactions, Anaphylactic Shock	Rare to Frequency Not Known
Vascular Disorders	Hypotension (Drop in blood pressure)	Uncommon
Skin and Subcutaneous	Rashes, SJS, Toxic Epidermal Necrolysis (TEN)	Rare to Very Rare

Safety Constraints for Specific Populations

Official labeling defines specific constraints for certain patient groups:

Older Adults and Renal/Hepatic Impairment: Due to the prolonged elimination of the medicine's metabolites, caution is required, and multiple high doses should be avoided.
Pregnancy (Third Trimester): Use is officially contraindicated during the last three months of pregnancy due to documented risks to the fetal heart and kidney function.
Pre-existing Conditions: The medicine is restricted in individuals with pre-existing bone marrow function impairment or a history of metamizole-induced agranulocytosis.

The regulatory safety structure emphasizes the continuous, non-dose-related risk of agranulocytosis and the need for vigilance, establishing a framework where use is guided by the official categorization of these severe, low-frequency risks.

Overdose and Emergency Response

The section describes the officially documented clinical manifestations and regulator-mandated emergency actions for an overdose of Algi Mabo (Sodium Metamizole).

Overdose exposure may present with documented signs involving several physiological systems. These commonly include gastrointestinal disturbances such as nausea, vomiting, and abdominal discomfort. Central Nervous System effects, like somnolence, headache, and vertigo, have also been officially documented. Cardiovascular and renal function may be impaired, potentially presenting as acute hypotension, tachycardia, or signs of renal dysfunction.

Regulators have classified overdose scenarios as potentially leading to severe, life-threatening outcomes, including circulatory shock, acute liver failure, and the severe blood disorder agranulocytosis. Given these risks, the official guidance requires individuals to seek immediate medical attention for any suspected overdose. Treatment must be immediately discontinued, and urgent medical help must be sought if any symptoms suggestive of blood dyscrasia (e.g., persistent fever, sore throat) are observed.

Management of an overdose is primarily symptomatic and supportive, as no specific antidote is known. Treatment procedures may include gastrointestinal decontamination, such as gastric lavage, if ingestion was recent. Furthermore, population-specific notes advise close medical supervision and avoidance of high doses in elderly patients or those with known hepatic or renal impairment, due to the potential for prolonged drug metabolite elimination.

Therapeutic Uses of Algi Mabo

Algi Mabo is applied across domains where additional symptomatic support is needed. It is considered relevant for patients experiencing symptoms related to physical discomfort, systemic imbalance, and heightened physiological activity. The agent is used for managing symptoms that create noticeable physiological strain, primarily encompassing conditions characterized by moderate to severe pain, high fever, and pain associated with smooth muscle spasm (colic).

This medication is commonly used to help with symptoms that may become intense or disruptive, such as those following surgery or trauma. It is applied in areas where short-term symptom management is appropriate, as well as in specialized therapeutic areas for managing symptoms that become more disruptive during flare-ups of chronic pain related to tumors. This supportive relief helps maintain a sense of stability when symptoms are more noticeable, assisting with functional stability during difficult episodes.

Quick Fact: Relief for Pain, Fever, and Spasm

Eligibility and Restrictions for Use

The eligibility for using Algi Mabo (Sodium Metamizole) is strictly defined by regulatory documents, which establish clear restrictions based on medical history, age, and physiological state.

Absolute Contraindications (Must Not Use)

Use is strictly prohibited for patients with:

A history of agranulocytosis or hypersensitivity caused by metamizole or related pyrazolones/pyrazolidines.
Impaired bone marrow function or diseases affecting the haematopoietic system.
Acute hepatic porphyria.
Infants below the age of 3 months or weighing less than 5 kg.
Women in the third trimester of pregnancy.

Age and Organ Function Restrictions

Use is conditional in several groups, as required by the European Medicines Agency (EMA) and other regulatory bodies:

Population Group	Eligibility Status
Children	Eligible above 3 months of age; dose must be determined by body weight.
Elderly/Debilitated	Use requires dose reduction due to potentially prolonged elimination of metabolites.
Renal/Hepatic Impairment	Multiple high doses must be avoided; long-term use in severe impairment is subject to insufficient regulatory experience.
Lactation	Advised against; regulatory guidelines suggest withholding breastfeeding for 48 hours after administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Algi Mabo (Sodium Metamizole) has a documented interaction profile in official regulatory documents, primarily focused on pharmacokinetic alterations and pharmacodynamic reinforcement or inhibition.

Key Documented Interaction Patterns

Interaction Type	Interacting Agents	Official Statement of Outcome
Exposure Reduction (PK)	Ciclosporin, Tacrolimus, Bupropion, Methadone, Valproate, Sertraline	Reduced plasma levels of the co-administered drug, potentially leading to decreased efficacy.
Effect Inhibition (PD)	Acetylsalicylic acid (low-dose Aspirin)	Inhibition of the anti-platelet aggregation effect.
Additive Toxicity (PD)	Methotrexate, Chlorpromazine	Increased risk of haematologic toxicity (Methotrexate) or additive hypothermia (Chlorpromazine).

Regulatory Constraints and Requirements

Enzyme Induction: Metamizole is officially documented as an inducer of CYP2B6 and CYP3A4, which is the mechanistic basis for the reduction in plasma concentration observed with certain co-administered medicines, requiring dose adjustment or therapeutic drug monitoring.
Timing Rule: To mitigate the interaction with Acetylsalicylic acid, regulatory guidance recommends that Aspirin should be taken at least 30 minutes before Metamizole.
Substance Restriction: The use of Alcohol is officially advised against during treatment.

This information is restricted to interaction statements found within governmental prescribing information and public assessment reports, defining the necessary co-administration constraints.

Mechanism of Action

Central Regulation of Pain and Temperature

The drug's active metabolites primarily act within the central nervous system (CNS) by targeting enzymes involved in the production of prostaglandins, specifically reducing the concentration of these chemical mediators in the brain. Concurrently, the mechanism involves modulating the body's intrinsic pain-inhibitory pathways, such as the endocannabinoid and opioidergic systems. This dual action influences the body's thermoregulatory set point to return an elevated body temperature toward its physiological baseline and adjusts the transmission of nociceptive signals in the spinal cord and brain.

Direct Modulation of Smooth Muscle Tone

Algi Mabo also operates through a distinct pathway that affects smooth muscle fibers in various organs. This mechanistic domain involves influencing the cellular mechanisms that regulate involuntary muscle contraction, potentially through the modulation of ion channels and calcium signaling critical for muscle tension. This targeted pathway interference results in a decrease in sustained contraction of smooth muscle and the reduction of involuntary muscle tension.

Dosage and Administration Information

How to Use Algi Mabo: Administration Guidelines

Algi Mabo (Sodium Metamizole) is used according to specific administration protocols. The guidelines below focus strictly on the principles for route, dosage, frequency, and administration context, as documented in available documentation.

Routes and Dose Limits

The medicine is authorized for several routes of administration to achieve systemic action, including oral (tablets, drops, solution), intravenous (IV) injection or infusion, intramuscular (IM) injection, and rectal (suppositories). The overarching principle of use is to administer the lowest effective dose.

The established dose limits define the standardized approach to use:

Adult Dosing: A single oral dose may be up to 1,000 mg. The total daily dose for oral administration must not exceed 4,000 mg. When administered by injection, the total daily dose is limited to 5,000 mg.
Pediatric Dosing: Dosage for children under 15 years is based on body weight (mg/kg), typically ranging from 8 to 16 mg per kg per single dose. Parenteral administration in infants under one year is restricted to the intramuscular route.

Frequency and Contextual Instructions

To prevent exceeding the daily limit, a single oral dose may be repeated up to four times daily, requiring a minimum interval of 6 to 8 hours between administrations. The medicine's onset of action when taken orally is generally expected 30 to 60 minutes after ingestion.

Special Conditions: For patients who are older or who have known kidney or liver impairment, the total administered dose must be reduced. This instruction is an adjustment defined to minimize the risk of drug accumulation.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Activity in Chronic Pain Studies

Research has evaluated the drug's activity in studies involving chronic pain. A large-scale Phase III trial investigated outcomes over a six-month period.

Pain Intensity: The trial examined changes in patient-reported pain scores (measured using the VAS scale) throughout the study duration.
Quality of Life: Investigators analyzed patient reports related to daily functioning and overall well-being.
Symptom Change Duration: Studies evaluated the link between consistent medication use and symptom changes.

Combination Therapy and Measured Outcomes

Studies investigated the combination therapy's effect on measured scores of patient mobility and overall discomfort in patients with advanced degenerative joint disease. The primary endpoints included:

Mobility Scores: Changes in the Lequesne Index scores were assessed.
Discomfort Levels: Patient-reported discomfort was tracked weekly using a standardized scale.
Time to Change: Research has explored the time until symptom changes were first noted following the initial dose.

Comparison to Other Studied Methods

Some studies compared the treatment's anti-inflammatory measures to those of older methods. These studies focused on measuring specific inflammatory biomarkers in the blood. Research has evaluated whether the co-administration of the drug with physical therapy alters measured outcomes.

Clinical Trial Monitoring and Response

Clinical trials included studies designed to monitor adverse events across diverse patient groups.

Elderly Patients: Studies included elderly patients with mild kidney impairment to examine their response to the treatment. The studies were designed to include analysis of changes in renal function markers.
Cardiovascular Response: Studies examined the activity of high doses in individuals with a history of heart conditions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Algi Mabo (FAQ)

Q: Is Algi Mabo considered a standard pain reliever like ibuprofen?

A: Official product information often reserves the use of Algi Mabo (metamizole) for the treatment of severe pain and high fever that has not been effectively managed by other common pain medicines. Regulatory documents state its indications include the management of severe pain and the reduction of fever, reflecting its specific activity profile, which differs from common over-the-counter options.

Q: How long can the pain relief from Algi Mabo be expected to last?

A: Regulatory dosing instructions indicate that a single dose should only be repeated after a minimum interval of 6 to 8 hours. This dosing instruction serves as a reference point for the typical length of time the medicine is expected to be active before the next dose is permitted.

Q: Can Algi Mabo be used for chronic, long-term pain management?

A: Regulatory documents primarily focus on the use of Algi Mabo for the management of acute, severe pain. While some studies have investigated its use over several months, official safety information emphasizes that the serious risk of agranulocytosis is not dose-dependent and can occur regardless of treatment duration.

Q: What symptoms related to blood cell count should I watch out for while taking Algi Mabo?

A: Official safety information advises patients to be vigilant for signs of a serious blood cell issue (agranulocytosis). These symptoms may include the sudden onset of fever, chills, a sore throat, or painful sores on the moist inner linings (mucosa) of the mouth, nose, or throat. If these symptoms occur, official guidance suggests immediately stopping the medication and seeking urgent medical evaluation.

Q: Can taking Algi Mabo mask symptoms of infection?

A: Yes, official safety information includes a warning that Algi Mabo’s fever-reducing effect may mask or conceal early signs of serious blood disorders (like agranulocytosis) or an infection. This masking can make it difficult to identify these conditions early.

Q: Are there any specific foods or drinks that should be avoided with Algi Mabo?

A: Regulatory documents explicitly advise against the use of alcohol during treatment with Algi Mabo. Official prescribing information generally focuses on the restriction of alcohol and does not typically detail other specific foods or drinks to avoid.

Q: Does Algi Mabo interact with any blood pressure medications?

A: The official list of undesirable effects includes hypotension (a sudden drop in blood pressure) as an uncommon side effect of the medicine itself. Official documents describe the drug's potential to cause hypotension, but specific, broad interactions with all classes of blood pressure medications are not detailed on the regulatory label.

Q: Why is Algi Mabo available in some countries but not others?

A: The varying availability of the medicine across the world is due to differing regulatory decisions made by national health authorities. These decisions are typically based on a country's assessment of the drug’s benefit-risk profile, particularly concerning the rare but serious risk of agranulocytosis.

Q: What kind of research has been done on the long-term safety of Algi Mabo?

A: Clinical trials have included studies lasting several months to monitor for the occurrence of adverse events. Safety evaluations have specifically focused on examining the response to the treatment in groups like elderly patients and those with mild kidney impairment.

Q: What is a 'pyrazolone' medicine, and how is it related to Algi Mabo?

A: Algi Mabo is officially classified as a pyrazolone derivative, which simply refers to its specific chemical structure. Regulatory documents use this classification to highlight that the medicine is a non-opioid analgesic that is chemically distinct from other common pain relievers.

Q: If I am taking immunosuppressants, is Algi Mabo safe to use?

A: Official documents state that Algi Mabo can cause a reduction in the plasma levels of certain immunosuppressants, such as ciclosporin and tacrolimus. This potential reduction in concentration may affect the immunosuppressant's efficacy, and dose adjustments may be considered by a healthcare provider.

Q: Can Algi Mabo be used for pain in children?

A: Regulatory documents confirm that Algi Mabo can be used in children above 3 months of age and weighing more than 5 kg, with dosing guided by their body weight.

Q: Does Algi Mabo help with fever that other medicines haven't helped with?

A: Yes, official indications for Algi Mabo often include its use in cases of high fever (pyrexia) that is described as refractory (not responding) to other standard therapeutic measures.

Q: Is Algi Mabo known by any other drug names?

A: Yes, the active ingredient in Algi Mabo, Sodium Metamizole, is also widely known by the non-proprietary name Dipyrone.

Q: Is Algi Mabo considered addictive or habit-forming?

A: Algi Mabo is officially classified as a non-opioid analgesic, meaning it does not belong to the class of narcotic medicines. Because of this classification, it is not considered addictive or habit-forming.

Q: Is Algi Mabo a prescription-only medicine?

A: In many countries where it is authorized, its regulatory status is designated as prescription-only in light of the potential risk of serious blood disorders.

Q: Can Algi Mabo change the color of urine?

A: Yes, official product information lists that a change in urine color to red is possible while using the medicine. This is due to the presence of a harmless metabolite and is expected to disappear after the treatment is stopped.

Q: Does Algi Mabo affect a person's ability to drive or use machinery?

A: Official warnings state that a person's reaction capacity may be impaired, particularly when high doses are used. Individuals should be cautious when driving or operating machinery, especially early in the treatment course.

Q: Are there any specific lab tests that might be needed while taking Algi Mabo?

A: Official documents note that if a blood problem, such as agranulocytosis, is suspected, a blood test to measure cell counts should be performed immediately.

Q: If I have a history of asthma or allergies, is the risk higher with Algi Mabo?

A: Official documents classify the drug as contraindicated (prohibited) for individuals with a history of bronchospasm (sudden airway narrowing) or other severe allergic reactions to metamizole. This includes those with certain types of asthma that are sensitive to pain relievers.

Q: Is there a maximum time Algi Mabo can be used for acute pain?

A: The medicine is generally indicated for the management of acute pain. If pain or fever persists or does not improve within a short specified period, official guidelines advise re-evaluating the treatment plan.

Q: Can Algi Mabo be taken on an empty stomach?

A: Official information states that the oral form is rapidly absorbed regardless of food intake. It is often recommended to take oral forms with or after a meal to help minimize potential digestive irritation.

Q: What if I take Algi Mabo and still have a high fever?

A: Since high fever can be an early symptom of a serious blood disorder, official safety guidance suggests that if a fever persists, unexpectedly worsens, or is accompanied by other warning signs, urgent medical evaluation is advised.

Q: Is it normal to feel a bit sleepy after taking Algi Mabo?

A: The official list of undesirable effects does not typically include drowsiness or sleepiness (somnolence) as a common side effect. However, individual responses to any medicine can vary, and caution is advised regarding driving or operating machinery.

Q: Why is Algi Mabo sometimes used for tumor pain?

A: Official regulatory documents specifically list one of the authorized indications as the treatment of pain associated with tumors (neoplasia). This use is based on the medicine's strong pain-relieving action.

Q: Does Algi Mabo affect the heart or blood pressure in a significant way?

A: Algi Mabo is officially contraindicated for use in the third trimester of pregnancy due to documented risks to the fetal heart. In other groups, a drop in blood pressure (hypotension) is listed as an uncommon side effect.

How should Algi Mabo be stored and disposed of?

Storage and Protection

Official regulatory documentation requires that Algi-Mabo (metamizole magnesium) be stored under specific environmental constraints. The medicine must be kept out of the sight and reach of children to prevent accidental ingestion. Storage conditions mandate protection from heat and humidity to maintain product integrity and stability until the official expiration date listed on the packaging. The product must not be used after this expiration date.

Storage Requirement	Official Condition
Child Safety	Keep out of the sight and reach of children.
Environmental Protection	Requires protection from heat and humidity.
Stability Limit	Do not use after the official expiration date.

Disposal Instructions

To ensure environmentally responsible disposal, official instructions require patients to consult a pharmacist regarding the proper handling of any unused or expired Algi-Mabo and its containers. This process is necessary to prevent the medicine from contaminating the environment.

Algi Mabo